

**Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)**

*(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 <sup>(1)</sup>)*

**(Text with EEA relevance)**

(2022/C 412/06)

**Decision granting an authorisation**

Reference of the decision <sup>(1)</sup>	Date of decision	Substance name	Holder(s) of the authorisation	Authorisation number	Authorised use	Date of expiry of review period	Reasons for the decision
C(2022) 7381	20 October 2022	4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO) EC No: -, CAS No:-	Merck KGaA, Frankfurter Strasse, 64293 Darmstadt, Germany	REACH/22/34/0	As raw material for the manufacturing of GMP Triton® X-100 Emprove® Expert in accordance with International Pharmaceutical Excipients Council Europe standards	4 January 2033	In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies.

<sup>(1)</sup> The decision is available on the European Commission website at: [Authorisation \(europa.eu\)](http://Authorisation.europa.eu).

<sup>(1)</sup> OJ L 396, 30.12.2006, p. 1.